PMID- 35018761
OWN - NLM
STAT- MEDLINE
DCOM- 20220311
LR  - 20221217
IS  - 2308-1430 (Electronic)
IS  - 0375-9660 (Print)
IS  - 0375-9660 (Linking)
VI  - 67
IP  - 6
DP  - 2021 Oct 25
TI  - [Morphological characteristics of pituitary adenomas in the phenocopy of multiple 
      endocrine neoplasia type 1].
PG  - 50-58
LID - 10.14341/probl12815 [doi]
AB  - BACKGROUND: Multiple endocrine neoplasia type 1 (MEN 1) is a rare autosomal 
      dominant disorder caused by mutations in the MEN1 gene, which encodes the menin 
      protein. If a patient has the MEN 1 phenotype in the absence of mutations 
      in the MEN1 gene, the condition is classified as a phenocopy of this syndrome. 
      Although significant progress has been made in understanding the function of 
      menin, its role in the oncogenesis of the endocrine glands is still being 
      elucidated. Due to its key role in physiological and pathological processes, the 
      assessment of the menin expression can provide valuable information. AIM: to 
      determine whether there are any differences in the expression of menin in the 
      pituitary adenomas (PA) in patients with phenocopy of MEN 1 (phMEN 1) and 
      genetically confirmed MEN 1 (gMEN 1) compared with their sporadic forms. 
      MATERIALS AND METHODS: immunohistochemical assessment of the menin expression was 
      carried out in PA of patients with gMEN 1, phMEN 1 and sporadic acromegaly (SA), 
      surgically treated in 2008-2020. IHC was performed using antibodies to menin, 
      PRL, GH, ACTH, FSH, TSH, Pit-1, T-box, ERA on previously prepared histological 
      section. RESULTS: The study included 35 samples of PA: gMEN 1 - 9 samples, 
      phMEN 1 - 12 (somatotropinomas + PHPT); CA - 14  samples. The patients were 
      comparable by gender, adenoma size, and drug intake. The gMEN  1 group differed 
      from phMEN 1 and SA by age (p = 0.0005). In patients with gMEN 1, the expression 
      of menin varied from no staining (5/9) to intense cytoplasm staining. Cytoplasmic 
      expression of menin was mainly present (11/12) in the phMEN 1. In the SA group, 
      there was no staining in 1 case; nuclear expression was detected in 6/14 cases. 
      The phMEN  1 group showed significantly higher cytoplasmic expression of menin 
      than the gMEN  1 group (p = 0.006). The gMEN 1 group also differed from the SA 
      group (p = 0.012). There were no statistically significant differences between 
      the phMEN 1 and SA groups (p = 0.049). CONCLUSION: It was revealed that the menin 
      expression, in general, is retained in phMEN 1 and SA groups, although with 
      different localization in the cell structure (nucleus and / or cytoplasm). At the 
      same time, the expression of menin varies greatly in patients with gMEN 1. 
      According to the data obtained, it can be assumed that the pathogenesis of PA 
      in phMEN 1 and SA may have similarities; however, there could be factors 
      contributing to the appearance of several tumors of the endocrine glands in one 
      person with phMEN 1. To understand this process, it is necessary to further study 
      the genes associated with MEN 1, epigenetic factors, signaling pathways in which 
      menin is involved.
FAU - Trukhina, D A
AU  - Trukhina DA
AD  - Endocrinology Research Centre.
FAU - Mamedova, E O
AU  - Mamedova EO
AD  - Endocrinology Research Centre.
FAU - Lapshina, A M
AU  - Lapshina AM
AD  - Endocrinology Research Centre.
FAU - Vasilyev, E V
AU  - Vasilyev EV
AD  - Endocrinology Research Centre.
FAU - Tiulpakov, A N
AU  - Tiulpakov AN
AD  - Endocrinology Research Centre; Research Centre for Medical Genetics.
FAU - Belaya, Zh E
AU  - Belaya ZE
AD  - Endocrinology Research Centre.
LA  - rus
PT  - Journal Article
DEP - 20211025
PL  - Russia (Federation)
TA  - Probl Endokrinol (Mosk)
JT  - Problemy endokrinologii
JID - 0140673
SB  - IM
MH  - *Acromegaly
MH  - *Adenoma/genetics
MH  - Humans
MH  - *Multiple Endocrine Neoplasia Type 1/genetics
MH  - Phenotype
MH  - *Pituitary Neoplasms/genetics
PMC - PMC9753811
EDAT- 2022/01/13 06:00
MHDA- 2022/03/12 06:00
PMCR- 2021/12/30
CRDT- 2022/01/12 06:55
PHST- 2021/09/13 00:00 [received]
PHST- 2021/10/25 00:00 [accepted]
PHST- 2021/10/14 00:00 [revised]
PHST- 2022/01/12 06:55 [entrez]
PHST- 2022/01/13 06:00 [pubmed]
PHST- 2022/03/12 06:00 [medline]
PHST- 2021/12/30 00:00 [pmc-release]
AID - 10.14341/probl12815 [doi]
PST - epublish
SO  - Probl Endokrinol (Mosk). 2021 Oct 25;67(6):50-58. doi: 10.14341/probl12815.